Many view as good news the report that the Centers for Disease Control and Prevention (CDC) administrators are meeting on Thursday to discuss possible adverse reactions to vaccines.
The discussion will focus on the reported adverse relationship between Johnson & Johnson’s COVID-19 vaccine and thrombocytopenia syndrome (TTS).
Thousands have reported blood clotting-related problems after receiving a COVID-19 vaccine. The United States National Library of Medicine National Institute of Health’s Nov. 29, 2021 report noted that in their study of 58 individuals, “All patients except one [experienced a negative health impact and]…death was the most prevalent outcome in all studies, except for one study in which most of the patients remained alive.”
The study detailed, “Vaccine-induced thrombotic thrombocytopenia (VITT) is an unknown nosological phenomenon secondary to inoculation with the COVID-19 vaccine.”
“Further studies are needed to better identify VITT’s pathophysiological mechanisms and…investigate the correlation of VITT with the different vaccine types…,” the study concluded.
Last month, CDC researchers reported that people who received the Johnson & Johnson vaccine were more likely to experience blood-clot issues than those who received other COVID vaccines, and also more likely than the unvaccinated.
Amid an outcry for more testing, transparency, and growing vaccine hesitancy, the CDC invited a panel of experts to advise the Board and make recommendations regarding the best path forward.
However, released information regarding the meeting notes that the presenters of information to CDC leadership are CDC employees.
Their objectivity in the matter has been questioned. Last week, the CDC Chief Dr. Anthony Fauci strongly advocated for vaccinations, including vaccinating minors, and for all groups to receive three or more boosters.
To date, U.S. drug regulators have only recognized a “causal relationship” between vaccinations and thrombocytopenia syndrome (TTS).
Similarly, the Food and Drug Administration (FDA) determined “the benefits of the vaccine outweighed its risks.”
Two facts are worth noting:
- The Vaccine Adverse Event Reporting System (VAERS) notes that less than 1% of adverse reactions are reported to their system; and
- A watchdog group recently found that VAERS has been underreporting adverse reaction stats.
Even so, the VAERS website notes that adverse reactions to COVID-19 vaccines in the last 12 months exceed the number of adverse reactions to all vaccines by about 400 percent.
In advance of Thursday’s meeting at the CDC, the FDA released a statement:
“The FDA continues to find that the known and potential benefits of the Janssen COVID-19 vaccine outweigh its known and potential risks in individuals 18 years of age and older. Individuals should speak to their health care provider to determine which COVID-19 vaccine is most appropriate for their own situation.”
According to a recent update from Fox News:
The CDC now recommends that Americans take the mRNA vaccines made by Pfizer and Moderna instead of the one-shot Johnson & Johnson vaccine due to rare but serious blood clots.
The agency’s Advisory Committee on Immunization Practices unanimously voted on Thursday to give a preferential recommendation to Moderna and Pfizer’s shots.
“More than 200 million Americans have completed their primary vaccine series, providing protection against COVID-19, preventing millions of cases and hospitalizations, and saving over a million lives,” CDC Director Rochelle Walensky said in a statement. “Today’s updated recommendation emphasizes CDC’s commitment to provide real-time scientific information to the American public.”
Scroll down to leave a comment and share your thoughts.
